Document resource
Background Myasthenia gravis (MG) is a chronic, autoimmune neuromuscular disorder characterised by fluctuating muscle weakness and fatigue. Effective management of complex and refractory cases requires a coordinated multidisciplinary team (MDT) approach.Objective Assess the current MDT landscape for the management of MG across Neuroscience Centres in England.Methods Cross-sectional survey methodology was employed utilising a questionnaire co-designed with MG specialist consultants and emailed to 25 NHS England Neuroscience Centres. Anonymised survey responses were aggregated and analysed as one dataset.Results Reponses were received from 19/25 (76%) centres covering 65% of the population in England. Most centres reported having neuromuscular or MG clinics. However, MDT provision varied between centres in relation to the nature of the MDT, healthcare professionals attending each MDT, whether MDTs were local or regional, and frequency of which the MDTs occurred. Some MDTs lacked a named neuromuscular specialist consultant.Conclusion MG is a complex heterogeneous disease with various treatment options. MDTs are needed to ensure treatment optimisation, equity of care and access to therapies. As treatments become available, variation in MDT provision may lead to inequalities in care, addressable through standardised specification for MG MDTs.Limitations Variation in individual interpretation of what MDT meant impacted survey responses chewamadduma1@sheffield.ac.uk